Calculating the Reportable Result from Retest Data - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Calculating the Reportable Result from Retest Data
Two methods to evaluate retest data following out-of-specification results.


Pharmaceutical Technology
Volume 37, Issue 2

Conclusion

Two established approaches for evaluating retest data following an OOS result have been described together with a method for generating a reportable result. These two approaches are not the only ones and companies are free to select and defend their own statistical approaches. Whichever approach is selected, the choice must be documented, justified, and described in an SOP.

References

1. United States vs. Barr Laboratories, Inc. Civil Action No. 92-1744, US District Court for the District of New Jersey: 812 F. Supp. 458. 1993 US Dist. Lexis 1932; Feb. 4, 1993, as amended Mar. 30, 1993.

2. FDA, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production (Rockville, MD, Oct. 2006).

3. European Compliance Academy (ECA) Analytical Quality Control Working Group website, http://www.gmp-compliance.org/eca_aqc_aboutus.html, accessed Jan. 7, 2012.

4. C. Burgess and B. Renger, ECA Standard Operating Procedure 01, Laboratory Data Management; Out of Specification (OOS) Results, Version 2, Aug. 2012.

5. L.D. Torbeck, Pharm. Tech. 35 (12), 28, 54 (2011).

6. M. Thompson and P.J. Lowthian, Notes on Statistics and Data Quality for Analytical Chemists, Section 7.6; Huber's H15 method, Imperial College Press, 2011, ISBN-10 184816-617 & references therein.

7. S.L.R. Ellison, V.J. Barwick, and T.J. Duguid Farrant, Practical Statistics for the Analytical Scientist, Section 5.3; Robust Statistics, Royal Society of Chemistry, 2009, ISBN 978-0-85404-131-2.

Chris Burgess, PhD,is an analytical scientist at Burgess Analytical Consultancy Limited, 'Rose Rae,' The Lendings, Startforth, Barnard Castle, Co Durham, DL12 9AB, UK; Tel: +44 1833 637 446;
; http://www.burgessconsultancy.com/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here